United States: The U.S. Food and Drug Administration has approved a bi-weekly dose of Johnson & Johnson's blood cancer therapy Tecvayli, the drugmaker said on Tuesday.
The approval allows the therapy to be used in a reduced dosing of 1.5 milligrams per kilogram every two weeks, in patients who have achieved and maintained a complete response or better for a minimum of six months.
Tecvayli was first approved in October 2022 for the treatment of adults with multiple myeloma that is hard to treat, or has come back after receiving at least four prior lines of certain classes of therapies.
Multiple myeloma is a type of blood cancer that affects types of white blood cells called plasma cells, found in bone marrow.
Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/bi-weekly-dose-johnson-johnsons-blood-cancer-therapy-gets-us-fda-approval-2024-02-20/
Read also: USFDA grants Breakthrough Therapy Designation for JnJ Nipocalimab for individuals at high risk for severe hemolytic disease of fetus, newborn
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!